Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2026)
Top diagnostic & research stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +28.50% per year, and are the best diagnostic & research stocks to buy now. Learn More.

Industry: Diagnostics & Research

Overview Zen Rating Price Value Growth Financials Momentum Sentiment Forecast

Diagnostics & Research is Zen Rated B and is the 33rd ranked industry out of 145 stock market industries

Ticker	Company	Market Cap	Price	Price Target	Upside/Downside	Consensus	Analysts	Fore. Revenue Growth	Fore. Earnings Growth	Forecast ROE	Forecast ROA
CDNA	CAREDX INC	$3.29B	$63.68	$61.67	-3.16%	Strong Buy	3	7.96%	-19.43%	20.13%	16.08%
SHC	SOTERA HEALTH CO	$5.23B	$18.34	$22.00	19.96%	Strong Buy	5	5.10%	27.76%	54.56%	10.98%
NEOG	NEOGEN CORP	$3.00B	$13.76	$14.00	1.74%	Strong Buy	1	0.39%	N/A	-1.17%	-0.73%
DGX	QUEST DIAGNOSTICS INC	$26.08B	$236.32	$247.14	4.58%	Buy	7	4.58%	11.35%	20.94%	9.29%
LH	LABCORP HOLDINGS INC	$25.11B	$309.64	$336.00	8.51%	Buy	10	5.27%	22.00%	21.60%	10.03%
NEO	NEOGENOMICS INC	$2.48B	$19.33	$17.00	-12.05%	Strong Buy	5	8.40%	N/A	10.24%	5.95%
IQV	IQVIA HOLDINGS INC	$44.50B	$270.37	$259.78	-3.92%	Strong Buy	9	5.19%	26.11%	48.23%	9.96%
CSTL	CASTLE BIOSCIENCES INC	$1.09B	$35.81	$41.75	16.59%	Strong Buy	4	8.72%	N/A	2.12%	1.78%
A	AGILENT TECHNOLOGIES INC	$48.71B	$172.79	$173.41	0.36%	Strong Buy	18	4.80%	13.67%	33.44%	17.63%
ILMN	ILLUMINA INC	$40.77B	$270.00	$200.60	-25.70%	Buy	15	5.99%	9.55%	42.96%	18.34%
TMO	THERMO FISHER SCIENTIFIC INC	$249.58B	$675.00	$613.62	-9.09%	Buy	13	5.09%	17.95%	24.21%	11.27%
IDXX	IDEXX LABORATORIES INC	$40.91B	$519.26	$681.25	31.20%	Buy	4	7.73%	10.30%	104.40%	48.90%
DHR	DANAHER CORP	$157.81B	$224.49	$213.92	-4.71%	Strong Buy	14	6.93%	22.16%	15.65%	8.91%
NTRA	NATERA INC	$59.47B	$412.56	$332.50	-19.41%	Strong Buy	20	16.24%	N/A	24.36%	16.70%
RVTY	REVVITY INC	$16.86B	$151.11	$119.64	-20.83%	Buy	12	3.83%	46.83%	11.36%	6.82%
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	$13.98B	$292.84	$308.50	5.35%	Strong Buy	10	1.92%	N/A	24.42%	9.21%
BDSX	BIODESIX INC	$307.04M	$29.10	$31.33	7.67%	Strong Buy	3	15.36%	N/A	-119.27%	-11.44%
WAT	WATERS CORP	$42.59B	$433.54	$432.90	-0.15%	Buy	19	18.29%	66.82%	13.87%	8.52%
XGN	EXAGEN INC	$211.24M	$8.72	$9.40	7.80%	Strong Buy	5	8.92%	N/A	8.01%	1.88%
BLLN	BILLIONTOONE INC	$5.81B	$123.08	$126.25	2.58%	Strong Buy	4	22.67%	25.41%	N/A	N/A
RDNT	RADNET INC	$5.57B	$70.79	$86.50	22.19%	Strong Buy	2	11.59%	N/A	8.71%	2.26%
OPK	OPKO HEALTH INC	$1.22B	$1.64	N/A	N/A	Hold	1	1.38%	N/A	N/A	N/A
MTD	METTLER TOLEDO INTERNATIONAL INC	$30.29B	$1,511.64	$1.44k	-4.77%	Buy	13	4.35%	9.35%	10,075.58%	35.20%
MEDP	MEDPACE HOLDINGS INC	$17.27B	$618.88	$580.88	-6.14%	Hold	8	6.50%	7.77%	151.78%	32.01%
PRPO	PRECIPIO INC	$42.34M	$23.65	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
STIM	NEURONETICS INC	$208.78M	$2.74	$5.50	100.73%	Strong Buy	2	8.05%	N/A	-130.62%	-17.73%
QGEN	QIAGEN NV	$9.14B	$44.18	$42.33	-4.18%	Buy	9	4.72%	14.81%	19.30%	11.00%
ICLR	ICON PLC	$13.30B	$172.33	$179.92	4.40%	Buy	12	3.09%	46.28%	12.35%	7.06%
TWST	TWIST BIOSCIENCE CORP	$11.46B	$182.83	$109.20	-40.27%	Buy	10	13.96%	N/A	24.25%	16.08%
QUCY	QUANTUM CYBER NV	$115.17M	$1.37	N/A	N/A	N/A	N/A	309.18%	N/A	N/A	N/A
GH	GUARDANT HEALTH INC	$23.79B	$177.25	$189.55	6.94%	Strong Buy	20	28.95%	N/A	-239.24%	27.88%
ADVB	ADVANCED BIOMED INC	$8.82M	$6.38	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GRAL	GRAIL INC	$5.67B	$126.89	$83.38	-34.29%	Buy	8	20.60%	N/A	-19.32%	-17.28%
ACRS	ACLARIS THERAPEUTICS INC	$758.07M	$5.15	$10.60	105.83%	Strong Buy	5	-10.84%	N/A	-106.29%	-73.69%
BIAF	BIOAFFINITY TECHNOLOGIES INC	$4.28M	$7.93	N/A	N/A	N/A	N/A	N/A	N/A	-118.40%	-58.57%
IMDX	INSIGHT MOLECULAR DIAGNOSTICS INC	$128.28M	$3.92	$8.50	116.84%	Strong Buy	2	160.05%	N/A	N/A	-70.29%
FLGT	FULGENT GENETICS INC	$610.84M	$22.20	$19.00	-14.41%	Hold	1	9.62%	N/A	-4.48%	-4.12%
FRNM	FREENOME INC	$1.71B	$15.99	$18.00	12.57%	Strong Buy	5	124.55%	N/A	N/A	-31.02%
MYGN	MYRIAD GENETICS INC	$398.86M	$4.17	$3.52	-15.66%	Hold	6	3.40%	N/A	18.30%	8.70%
NDRA	ENDRA LIFE SCIENCES INC	$9.06M	$6.04	$25.00	313.91%	Buy	1	N/A	N/A	-73.71%	-58.56%
TRIB	TRINITY BIOTECH PLC	$4.22M	$6.76	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-5.93%
MBAI	MBODY AI LTD	$4.60M	$4.59	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ISPC	ISPECIMEN INC	$3.17M	$1.26	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BNR	BURNING ROCK BIOTECH LTD	$202.00M	$18.60	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XWEL	XWELL INC	$7.68M	$0.89	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VNRX	VOLITIONRX LTD	$3.54M	$0.26	$12.00	4,533.20%	Buy	3	120.69%	N/A	-25.97%	100.63%
PSNL	PERSONALIS INC	$1.76B	$16.46	$15.17	-7.86%	Buy	4	30.86%	N/A	-26.87%	-20.24%
DRIO	DARIOHEALTH CORP	$64.97M	$6.63	$10.00	50.83%	Strong Buy	3	21.51%	N/A	16.51%	9.42%
SERA	SERA PROGNOSTICS INC	$80.48M	$2.04	$6.00	194.12%	Buy	1	364.56%	N/A	-38.63%	-26.44%
MDXH	MDXHEALTH SA	$2.90M	$0.57	$2.17	283.54%	Strong Buy	3	9.18%	N/A	N/A	N/A

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Sep 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

1. Caredx (NASDAQ:CDNA)

Caredx (NASDAQ:CDNA) is the #1 top diagnostic & research stock out of 50 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Caredx (NASDAQ:CDNA) is: Value: C, Growth: B, Momentum: A, Sentiment: B, Safety: C, Financials: A, and AI: C.

Caredx (NASDAQ:CDNA) has a Due Diligence Score of 53, which is 24 points higher than the diagnostic & research industry average of 29.

CDNA passed 18 out of 33 due diligence checks and has strong fundamentals. Caredx has seen its stock return 328.24% over the past year, overperforming other diagnostic & research stocks by 291 percentage points.

Caredx has an average 1 year price target of $61.67, a downside of -3.16% from Caredx's current stock price of $63.68.

Caredx stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Caredx, 66.67% have issued a Strong Buy rating, 0% have issued a Buy, 33.33% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Sotera Health Co (NASDAQ:SHC)

Sotera Health Co (NASDAQ:SHC) is the #2 top diagnostic & research stock out of 50 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Sotera Health Co (NASDAQ:SHC) is: Value: B, Growth: C, Momentum: C, Sentiment: B, Safety: B, Financials: B, and AI: C.

Sotera Health Co (NASDAQ:SHC) has a Due Diligence Score of 40, which is 11 points higher than the diagnostic & research industry average of 29.

SHC passed 14 out of 33 due diligence checks and has average fundamentals. Sotera Health Co has seen its stock return 18.02% over the past year, underperforming other diagnostic & research stocks by -19 percentage points.

Sotera Health Co has an average 1 year price target of $22.00, an upside of 19.96% from Sotera Health Co's current stock price of $18.34.

Sotera Health Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Sotera Health Co, 80% have issued a Strong Buy rating, 0% have issued a Buy, 20% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Neogen (NASDAQ:NEOG)

Neogen (NASDAQ:NEOG) is the #3 top diagnostic & research stock out of 50 with a Zen Rating of B. Stocks with a rating of B have had an average return of +17.17% per year. Learn more.

The Component Grade breakdown for Neogen (NASDAQ:NEOG) is: Value: C, Growth: B, Momentum: A, Sentiment: B, Safety: C, Financials: C, and AI: C.

Neogen (NASDAQ:NEOG) has a Due Diligence Score of 16, which is -13 points lower than the diagnostic & research industry average of 29. Although this number is below the industry average, our proven quant model rates NEOG as a "B".

NEOG passed 5 out of 33 due diligence checks and has weak fundamentals. Neogen has seen its stock return 156.72% over the past year, overperforming other diagnostic & research stocks by 120 percentage points.

Neogen has an average 1 year price target of $14.00, an upside of 1.74% from Neogen's current stock price of $13.76.

Neogen stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Neogen, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 7 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) has an annual dividend yield of 5.18%, which is 4 percentage points higher than the diagnostic & research industry average of 1.29%.

Qiagen Nv's dividend payout ratio of 243.6% indicates that its high dividend yield might not be sustainable for the long-term.

2. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.4%, which is the same as the diagnostic & research industry average of 1.29%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 34.8% indicates that its dividend yield is sustainable for the long-term.

3. Labcorp Holdings (NYSE:LH)

Labcorp Holdings (NYSE:LH) has an annual dividend yield of 0.93%, which is the same as the diagnostic & research industry average of 1.29%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 23.7% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -0.12% in the last day, and up 5.22% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are down.

What are the most undervalued diagnostic & research stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

1. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) is the most undervalued diagnostic & research stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Qiagen Nv has a valuation score of 29, which is 17 points higher than the diagnostic & research industry average of 12. It passed 2 out of 7 valuation due diligence checks.

Qiagen Nv's stock has gained 0.57% in the past year. It has underperformed other stocks in the diagnostic & research industry by -36 percentage points.

2. Icon (NASDAQ:ICLR)

Icon (NASDAQ:ICLR) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Icon has a valuation score of 43, which is 31 points higher than the diagnostic & research industry average of 12. It passed 3 out of 7 valuation due diligence checks.

Icon's stock has gained 6.03% in the past year. It has underperformed other stocks in the diagnostic & research industry by -31 percentage points.

3. Sotera Health Co (NASDAQ:SHC)

Sotera Health Co (NASDAQ:SHC) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Sotera Health Co has a valuation score of 14, which is 2 points higher than the diagnostic & research industry average of 12. It passed 1 out of 7 valuation due diligence checks.

Sotera Health Co's stock has gained 18.02% in the past year. It has underperformed other stocks in the diagnostic & research industry by -19 percentage points.

Are diagnostic & research stocks a good buy now?

51.22% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to fall by -2.49% over the next year.

5.13% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 20.51% of diagnostic & research stocks are rated B (Buy), 66.67% are rated C (Hold), 7.69% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 9.38x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.

Diagnostic & Research Stocks FAQ

1. Caredx (NASDAQ:CDNA)

2. Sotera Health Co (NASDAQ:SHC)

3. Neogen (NASDAQ:NEOG)

1. Qiagen Nv (NYSE:QGEN)

2. Quest Diagnostics (NYSE:DGX)

3. Labcorp Holdings (NYSE:LH)

1. Qiagen Nv (NYSE:QGEN)

2. Icon (NASDAQ:ICLR)

3. Sotera Health Co (NASDAQ:SHC)

Company

Stock Tools

Stock Ideas